Table 3.
Comparison of pretreatment factors between groups of patients who achieved disease control with atezolizumab plus bevacizumab combination therapy and those who did not.
| Characteristics | Patients with CR/PR/SD (n = 26) | Patients with PD (n = 13) | p Value |
|---|---|---|---|
| Age (years) | 68.8 (7.38) | 70.1 (6.46) | 0.621 |
| Sex (male/female) | 23/3 | 11/2 | 0.735 |
| Etiology (viral/non-viral) | 12/14 | 6/7 | 1.000 |
| BCLC stage (B/C) | 14/12 | 7/6 | 1.000 |
| Treatment history with MTA (yes/no) | 16/10 | 9/4 | 0.637 |
| Aspartate aminotransferase (IU/L) | 53.4 (43.0) | 46.7 (24.1) | 0.964 |
| Alanine aminotransferase (IU/L) | 38.7 (27.0) | 36.4 (20.1) | 0.777 |
| Platelets (×104/μL) | 16.0 (5.96) | 14.2 (5.23) | 0.465 |
| Child-Pugh score (5A/6A or 7B) | 18/8 | 7/6 | 0.345 |
| ALBI score | −2.47 (0.41) | −2.32 (0.37) | 0.205 |
| Modified ALBI grade (1/2a or 2b) | 12/14 | 3/10 | 0.163 |
| α-fetoprotein (ng/mL) | 1341 (5305) | 7436 (15772) | 0.022 |
| Des-γ-carboxy prothrombin (mAU/mL) | 12751 (40523) | 2529 (3590) | 0.318 |
| FIB-4 index | 4.34 (3.38) | 4.83 (3.08) | 0.475 |
| Neutrophil-to-lymphocyte ratio (NLR) | 2.47 (1.09) | 4.48 (3.22) | 0.013 |
| Platelet-to-lymphocyte ratio (PLR) | 134 (58.1) | 163 (83.0) | 0.270 |
| Lymphocyte-to-monocyte ratio (LMR) | 2.85 (1.08) | 2.68 (1.36) | 0.551 |
Values are presented as mean (standard deviation) or number. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; BCLC, Barcelona Clinic Liver Cancer; MTA, molecular-targeted agent; ALBI, albumin-bilirubin; AU, arbitrary unit; FIB-4, fibrosis-4.